ST
Synspira Therapeutics develops targeted therapies for cystic fibrosis and other rare diseases using rational drug design to enhance treatment efficacy. The company aims to improve patient outcomes by addressing the underlying genetic and biochemical mechanisms of these conditions.
Updated 20 months ago
Funding
$14M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CF
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Synspira Therapeutics develops targeted therapies for cystic fibrosis and other rare diseases using rational drug design to enhance treatment efficacy. The company aims to improve patient outcomes by addressing the underlying genetic and biochemical mechanisms of these conditions.